Generic Rezzayo Availability
Last updated on Dec 12, 2024.
Rezzayo is a brand name of rezafungin, approved by the FDA in the following formulation(s):
REZZAYO (rezafungin acetate - powder;intravenous)
-
Manufacturer: MUNDIPHARMA
Approval date: March 22, 2023
Strength(s): EQ 200MG BASE/VIAL [RLD]
Has a generic version of Rezzayo been approved?
No. There is currently no therapeutically equivalent version of Rezzayo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rezzayo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dosing regimens for echinocandin class compounds
Patent 10,702,573
Issued: July 7, 2020
Inventor(s): Radhakrishnan Balasingam & James & Jr. Kenneth Duke & Vaidya Anuradha & Polowy Karen
Assignee(s): Cidara Therapeutics, Inc.The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.
Patent expiration dates:
- March 14, 2033✓✓✓
- March 14, 2033
-
Compositions and methods for the treatment of fungal infections
Patent 11,197,909
Issued: December 14, 2021
Inventor(s): Bartizal Kenneth & Daruwala Paul & Hughes David & Hughes Martin Patrick & Malkar Navdeep B. & Radhakrishnan Balasingam & Vaidya Anuradha
Assignee(s): Cidara Therapeutics, Inc.The disclosure features non-irritating pharmaceutical compositions containing CD101 in pharmaceutical acceptable salt (e.g., CD101 acetate) or neutral form. The pharmaceutical compositions can be intravenously administered to a subject to treat fungal infections (e.g., candidiasis) in the subject.
Patent expiration dates:
- July 14, 2038✓✓✓
- July 14, 2038
-
Patent 11,654,196
Patent expiration dates:
- March 2, 2032✓✓✓
- March 2, 2032
-
Patent 11,712,459
Patent expiration dates:
- March 15, 2037✓✓
- March 15, 2037
-
Patent 11,819,533
Patent expiration dates:
- July 11, 2038✓✓✓
- July 11, 2038
-
Antifungal agents and uses thereof
Patent 8,722,619
Issued: May 13, 2014
Inventor(s): James & Jr. Kenneth Duke & Laudeman Christopher Patrick
Assignee(s): Seachaid Pharmaceuticals, Inc.The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.
Patent expiration dates:
- March 2, 2032✓✓✓
- March 2, 2032
-
Dosing regimens for echinocandin class compounds
Patent 9,526,835
Issued: December 27, 2016
Inventor(s): Radhakrishnan Balasingam & James & Jr. Kenneth Duke & Vaidya Anuradha & Polowy Karen
Assignee(s): Cidara Therapeutics, Inc.The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.
Patent expiration dates:
- March 14, 2033✓✓✓
- March 14, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 22, 2028 - NEW CHEMICAL ENTITY
- March 22, 2030 - FOR USE IN PATIENTS 18 YEARS OF AGE OR OLDER WHO HAVE LIMITED OR NO ALTERNATIVE OPTIONS FOR THE TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS
- March 22, 2033 - GENERATING ANTIBIOTIC INCENTIVES NOW
- March 22, 2035 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Rezzayo (rezafungin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: echinocandins
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
